Design of Artificial Peptide Against HIV-1 Based on the Heptad-Repeat Rules and Membrane-Anchor Strategies
Open Access
- 12 December 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (12) , 1881
Abstract
Objective: The six-helix bundle (6-HB) is critical for HIV-1 membrane fusion. To disrupt this process, peptide inhibitors have been meticulously designed to target interactions within the 6-HB regions, thereby blocking membrane fusion and exerting inhibitory effects. Current peptide inhibitors like Enfuvirtide suffer from drug resistance and short in vivo half-life. This study aims to design novel anti-HIV-1 peptides by integrating heptad-repeat rules and membrane-anchor strategies. Methods: Artificial peptides were designed using HR rules from the HIV-1 gp41 6-HB motif and membrane-anchor modifications. Results: EK35S-Palm has emerged as a highly promising candidate for HIV-1 inhibition, exhibiting robust binding affinity to the target and effectively impeding the 6-HB spontaneous formation. Discussion: HR-based design avoids viral sequence homology, and membrane anchoring enhances local agent concentration, improving pharmacokinetics. The HR binding and membrane stabilization of EK35S-Palm provide synergistic inhibition. Conclusions: Integrating HR structural design with membrane-anchor strategies yields potent HIV-1 fusion inhibitors. EK35S-Palm demonstrates superior efficacy and stability over current therapies. These approaches hold great potential for overcoming the current therapy limitations and advancing the more effective and durable HIV-1 fusion inhibitors.Keywords
Funding Information
- Science and Technology Project of Inner Mongolia Autonomous Region of China (2025KJHZ0064)
- State Key Laboratory of Natural and Biomimetic Drugs (KF2025034)
- Sub-project of Quality Enhancement and Cultivation Discipline for the Pharmacy College of Inner Mongolia Medical University (YXY2024TZ701)
- Scientific Staring Foundation for Ph.D. Research of Inner Mongolia Medical University (YKD2025BSQD023)
- “Cultivation of Excellence” Project for Science and Technology Innovation of Inner Mongolia Medical University (YCPY2025005)
- Undergraduate innovation and entrepreneurship training program of Inner Mongolia Medical University (101322025011)
- Undergraduate innovation and entrepreneurship training program of Inner Mongolia Medical University (101322025051)
- Basic and Applied Basic Research Science and Technology Program Projects of Hohhot (2024-GUI-JI-20)
This publication has 21 references indexed in Scilit:
- Design of coiled-coil N-peptides against HIV-1 based on a CADD strategyOrganic & Biomolecular Chemistry, 2024
- An N-terminal heptad repeat trimer-based peptide fusion inhibitor exhibits potent anti-H1N1 activityBioorganic & Medicinal Chemistry, 2024
- Improving Anti-HIV activity and pharmacokinetics of enfuvirtide (T20) by modification with oligomannoseEuropean Journal of Medicinal Chemistry, 2024
- Antiviral Protein–Protein Interaction InhibitorsJournal of Medicinal Chemistry, 2024
- Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus InfectionJournal of Medicinal Chemistry, 2021
- De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug DiscoveryJournal of Medicinal Chemistry, 2018
- Line tension at lipid phase boundaries as driving force for HIV fusion peptide-mediated fusionNature Communications, 2016
- Conjugation of a Nonspecific Antiviral Sapogenin with a Specific HIV Fusion Inhibitor: A Promising Strategy for Discovering New Antiviral TherapeuticsJournal of Medicinal Chemistry, 2014
- Design of highly potent HIV fusion inhibitors based on artificial peptide sequencesChemical Communications, 2012
- Electrostatically constrained α-helical peptide inhibits replication of HIV-1 resistant to enfuvirtideThe International Journal of Biochemistry & Cell Biology, 2009